These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33596317)

  • 1. Modelling trachoma post-2020: opportunities for mitigating the impact of COVID-19 and accelerating progress towards elimination.
    Borlase A; Blumberg S; Callahan EK; Deiner MS; Nash SD; Porco TC; Solomon AW; Lietman TM; Prada JM; Hollingsworth TD
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):213-221. PubMed ID: 33596317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of the COVID-19 pandemic in eliminating trachoma as a public health problem.
    Blumberg S; Borlase A; Prada JM; Solomon AW; Emerson P; Hooper PJ; Deiner MS; Amoah B; Hollingsworth TD; Porco TC; Lietman TM
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):222-228. PubMed ID: 33449114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of modelling to modify trachoma elimination strategies affected by the COVID-19 pandemic.
    Emerson PM; Hooper PJ; Gebre T
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):211-212. PubMed ID: 33421962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
    Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study.
    Borlase A; Le Rutte EA; Castaño S; Blok DJ; Toor J; Giardina F; Davis EL;
    Lancet Glob Health; 2022 Nov; 10(11):e1600-e1611. PubMed ID: 36240827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies.
    Kura K; Ayabina D; Toor J; Hollingsworth TD; Anderson RM
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):236-244. PubMed ID: 33515038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delays in lymphatic filariasis elimination programmes due to COVID-19, and possible mitigation strategies.
    Prada JM; Stolk WA; Davis EL; Touloupou P; Sharma S; Muñoz J; Caja Rivera RM; Reimer LJ; Michael E; de Vlas SJ; Hollingsworth TD
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):261-268. PubMed ID: 33515454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from the field: delivering trachoma mass drug administration safely in a COVID-19 context.
    Amanyi-Enegela JA; Burn N; Dirisu O; Ebenso B; Sankar G; Ishaya R; Ogoshi C; Kumbur J; Ekweremadu B; Qureshi BM
    Trans R Soc Trop Med Hyg; 2021 Oct; 115(10):1102-1105. PubMed ID: 34291283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antibiotic distribution strategies and the potential impact of facial cleanliness and environmental improvements for the sustained control of trachoma: a modelling study.
    Pinsent A; Burton MJ; Gambhir M
    BMC Med; 2016 May; 14(1):71. PubMed ID: 27194136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forecasting the elimination of active trachoma: An empirical model.
    Renneker KK; Emerson PM; Hooper PJ; Ngondi JM
    PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010563. PubMed ID: 35816486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a single round of mass drug administration with azithromycin on active trachoma and ocular Chlamydia trachomatis prevalence and circulating strains in The Gambia and Senegal.
    Harding-Esch EM; Holland MJ; Schémann JF; Sillah A; Sarr B; Christerson L; Pickering H; Molina-Gonzalez S; Sarr I; Andreasen AA; Jeffries D; Grundy C; Mabey DCW; Herrmann B; Bailey RL
    Parasit Vectors; 2019 Oct; 12(1):497. PubMed ID: 31640755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of azithromycin mass drug administration on trachoma: a systematic review.
    Xiong T; Yue Y; Li WX; Choonara I; Qazi S; Chen HJ; Tang J; Shi J; Wang H; Zeng LN; Xia B; Qiao LN; Qu Y; Mu DZ
    Chin Med J (Engl); 2021 Sep; 134(24):2944-2953. PubMed ID: 34665571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the impact of COVID-19-related programme interruptions on visceral leishmaniasis in India.
    Le Rutte EA; Coffeng LE; Muñoz J; de Vlas SJ
    Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):229-235. PubMed ID: 33580952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass drug administration for trachoma: how long is not long enough?
    Jimenez V; Gelderblom HC; Mann Flueckiger R; Emerson PM; Haddad D
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003610. PubMed ID: 25799168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical Modelling of Trachoma Transmission, Control and Elimination.
    Pinsent A; Blake IM; Basáñez MG; Gambhir M
    Adv Parasitol; 2016; 94():1-48. PubMed ID: 27756453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Towards the trachoma elimination target in the Southern region of Ethiopia: How well is the SAFE strategy being implemented?
    Asfaw M; Zolfo M; Negussu N; Tadesse F; Tadele T; Sisay A; Seyum D; Gezmu T; Senkoro M; Owiti P; Adriaensen W
    J Infect Dev Ctries; 2020 Jun; 14(6.1):3S-9S. PubMed ID: 32614789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and community acceptability of enhanced antibiotic distribution approaches for trachoma in the Republic of South Sudan: enhancing the A in SAFE (ETAS) study protocol.
    Sanders AM; Makoy S; Deathe AR; Ohidor S; Jesudason TC; Nute AW; Odongi P; Boniface L; Abuba S; Delahaut AS; Sebit W; Niquette J; Callahan EK; Walker DG; Nash SD
    BMC Ophthalmol; 2023 Feb; 23(1):51. PubMed ID: 36747194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of Trachoma Transmission and Their Policy Implications: From Control to Elimination.
    Lietman TM; Pinsent A; Liu F; Deiner M; Hollingsworth TD; Porco TC
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S275-S280. PubMed ID: 29860288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where do we go from here? Prevalence of trachoma three years after stopping mass distribution of antibiotics in the regions of Kayes and Koulikoro, Mali.
    Bamani S; King JD; Dembele M; Coulibaly F; Sankara D; Kamissoko Y; Ting J; Rotondo LA; Emerson PM
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e734. PubMed ID: 20625555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global progress toward the elimination of active trachoma: an analysis of 38 countries.
    Renneker KK; Abdala M; Addy J; Al-Khatib T; Amer K; Badiane MD; Batcho W; Bella L; Bougouma C; Bucumi V; Chisenga T; Dat TM; Dézoumbé D; Elshafie B; Garae M; Goepogui A; Hammou J; Kabona G; Kadri B; Kalua K; Kanyi S; Khan AA; Marfo B; Matendechero S; Meite A; Minnih A; Mugume F; Olobio N; Omar FJ; Phiri I; Sanha S; Sharma S; Seife F; Sokana O; Taoaba R; Tesfazion A; Traoré L; Uvon N; Yaya G; Logora MY; Hooper PJ; Emerson PM; Ngondi JM
    Lancet Glob Health; 2022 Apr; 10(4):e491-e500. PubMed ID: 35303459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.